Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for PHIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.003M
December 31, 2025 0.00
September 30, 2025 -0.007M
June 30, 2025 -0.003M
March 31, 2025 -0.002M
December 31, 2024 0.008M
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 -0.005M
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 -0.007M
June 30, 2022 -0.01M
March 31, 2022 -0.104M
December 31, 2021 0.00
September 30, 2021 -0.03M
June 30, 2021 -0.015M
March 31, 2021 -0.006M
December 31, 2020 -0.001M
September 30, 2020 -0.008M
June 30, 2020 0.00
Date Value
March 31, 2020 -0.01M
December 31, 2019 0.005M
September 30, 2019 -0.061M
June 30, 2019 -0.015M
March 31, 2019 -0.001M
December 31, 2018 -0.005M
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 -0.015M
June 30, 2017 -0.186M
March 31, 2017 0.098M
December 31, 2016 1.848M
September 30, 2016 -0.002M
June 30, 2016 1.50M
March 31, 2016 2.00M
December 31, 2015 2.482M
September 30, 2015 0.00
June 30, 2015 -8.031M
March 31, 2015 -0.008M
December 31, 2014 4.991M
September 30, 2014 -5.015M
June 30, 2014 2.941M
March 31, 2014 0.00

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Imunon, Inc. -0.0691M
Agenus, Inc. 0.267M
Amgen, Inc. -569.00M
Anika Therapeutics, Inc. -1.28M
BioCryst Pharmaceuticals, Inc. -110.15M